OneSource Specialty Pharma Limited has achieved a significant regulatory milestone with the Saudi Food and Drug Authority (SFDA) approval of its generic Ozempic (semaglutide) for the Saudi Arabian market. The approval enables the company to commercialise the diabetes therapy through an exclusive partnership with Hikma Pharmaceuticals PLC across the Middle East and North Africa (MENA) region.

Strategic Partnership Details

The exclusive agreement establishes a clear division of responsibilities between the two pharmaceutical companies:

Market Significance

The approval represents OneSource's strategic entry into Saudi Arabia, identified as one of the largest markets globally for GLP-1 therapies. The partnership positions both companies to capitalise on the rising demand for semaglutide while expanding access to affordable generic alternatives across the region.

Mr. Neeraj Sharma, CEO & MD of OneSource Specialty Pharma Limited, expressed enthusiasm about the development: "We are extremely excited to secure SFDA approval for semaglutide in Saudi Arabia, one of the largest GLP-1 market globally with significant long-term potential. We are confident that collaborating with Hikma, the largest pharmaceutical company in the MENA region by sales, will give us a strong platform to scale access to this important therapy across both private and institutional customers."

Company Capabilities

OneSource operates as a pure-play specialty pharmaceutical CDMO with comprehensive manufacturing capabilities:

Partnership Leverage

Hikma Pharmaceuticals brings substantial commercial expertise to the partnership, operating as the largest pharmaceutical company in MENA based on sales. The company maintains extensive commercial reach and institutional relationships across the region, providing the infrastructure necessary to scale access to semaglutide therapy.

The collaboration combines OneSource's manufacturing capabilities with Hikma's established market presence, creating a comprehensive approach to generic semaglutide distribution in the MENA region. This strategic alignment supports both companies' shared objective of increasing patient access to high-quality, affordable generic alternatives.

Source:

Onesource Specialty Pharma Limited has disclosed another substantial acquisition of shares by its promoter group entity Tenshi Pharmaceuticals Private Limited on January 30, 2026. This latest acquisition follows the previous purchase on January 28, 2026, representing continued strategic increase in promoter holding through open market purchases, as disclosed under SEBI regulations.

Latest Acquisition Details

Tenshi Pharmaceuticals Private Limited acquired 75,000 equity shares of Onesource Specialty Pharma Limited through open market purchase. The transaction details are presented below:

Updated Shareholding Pattern

The latest acquisition resulted in further changes to the promoter group's overall shareholding in the company. The comparative shareholding position shows the cumulative impact of recent transactions:

Promoter Group Structure

The disclosure identifies Tenshi Pharmaceuticals Private Limited as the acquirer, with several entities and individuals acting as persons acting in concert (PAC). The PAC group includes:

• Karuna Business Solutions LLP
• Pronomz Ventures LLP
• Arco Lab Private Limited
• Arun Kumar Pillai
• Vineetha Mohanakumar Pillai
• Padmakumar Karunakaran Pillai
• Sajitha Pillai
• Rajitha Gopalakrishnan
• Aditya Arun Kumar
• Hemalatha Pillai

Company Capital Structure

The company's equity share capital remained unchanged following this acquisition. The total equity share capital stands at 11,46,21,201 equity shares of Rs. 1 each, fully paid up. These acquisitions represent internal restructuring within the promoter group rather than any change to the overall capital structure.

Regulatory Compliance

The disclosure was made by Shridhara Kela, Director of Tenshi Pharmaceuticals Private Limited (DIN: 02592314), in compliance with Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The company is listed on both BSE Limited (Scrip Code: 544292) and National Stock Exchange of India Limited (Scrip Code: ONESOURCE).